X

Regeneron Pharmaceuticals (REGN): Q4 2019 Earnings Snapshot

— Regeneron Pharmaceuticals (NASDAQ: REGN) reported Q4 2019 earnings of $7.50 per share, vs. $6.92 expected.

— Revenues grew 13% to $2.17 billion, vs. $2.11 billion expected.

— Net product sales were $1.28 billion.

— EYLEA net product sales in the US were $1.22 billion.

— Sanofi and Bayer collaboration revenues were $748 million.

— R&D expenses totaled $683 million.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Related Post